NO20062198L - Bradykinin B1 reseptorantagonister - Google Patents
Bradykinin B1 reseptorantagonisterInfo
- Publication number
- NO20062198L NO20062198L NO20062198A NO20062198A NO20062198L NO 20062198 L NO20062198 L NO 20062198L NO 20062198 A NO20062198 A NO 20062198A NO 20062198 A NO20062198 A NO 20062198A NO 20062198 L NO20062198 L NO 20062198L
- Authority
- NO
- Norway
- Prior art keywords
- bradykinin
- receptor antagonists
- peptides
- conjugated peptides
- present
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/043—Kallidins; Bradykinins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/18—Kallidins; Bradykinins; Related peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Addiction (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
Abstract
Foreliggende oppfinnelse vedrører visse biologisk aktive peptider og konjugerte peptider som kan anvendes terapeutisk eller profylaktisk mot sykdommer eller tilstander forbundet med BI som det forårsakende middel. I en foretrukket utførelessform av oppfinnelsen blir biologisk aktive PEG-konjugerte peptider tilveiebrakt. I et aspekt av foreliggende oppfinnelse er farmasøytisk aktive PEG-konjugerte peptider ifølge oppfinnelsen anvendelige for å behandle inflammasjon eller smerte.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51391303P | 2003-10-22 | 2003-10-22 | |
US53892904P | 2004-01-24 | 2004-01-24 | |
US10/972,236 US7605120B2 (en) | 2003-10-22 | 2004-10-21 | Antagonists of the brandykinin B1 receptor |
PCT/US2004/034976 WO2005042027A2 (en) | 2003-10-22 | 2004-10-22 | Antagonists of the bradykinin b1 receptor |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20062198L true NO20062198L (no) | 2006-07-18 |
Family
ID=34990807
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20062198A NO20062198L (no) | 2003-10-22 | 2006-05-15 | Bradykinin B1 reseptorantagonister |
Country Status (15)
Country | Link |
---|---|
US (4) | US7605120B2 (no) |
EP (1) | EP1677830B1 (no) |
JP (1) | JP4896728B2 (no) |
KR (2) | KR20060105757A (no) |
AU (1) | AU2004285467A1 (no) |
BR (1) | BRPI0415755A (no) |
CA (1) | CA2545499A1 (no) |
EA (1) | EA009294B1 (no) |
EC (1) | ECSP066575A (no) |
ES (1) | ES2395546T3 (no) |
IL (1) | IL175084A0 (no) |
MA (1) | MA28160A1 (no) |
NO (1) | NO20062198L (no) |
SG (1) | SG149872A1 (no) |
WO (1) | WO2005042027A2 (no) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL1750683T3 (pl) * | 2004-04-23 | 2013-05-31 | Amgen Inc | Formuły o przedłużonym uwalnianiu |
MX2007013213A (es) * | 2005-04-25 | 2007-12-12 | Amgen Inc | Composiciones de liberacion prolongada de peptidos biodegradables que contienen porogenos. |
US8288339B2 (en) | 2006-04-20 | 2012-10-16 | Amgen Inc. | GLP-1 compounds |
US7403325B2 (en) * | 2006-05-19 | 2008-07-22 | Xerox Corporation | Electrophoretic display device |
CA2840407A1 (en) | 2007-05-22 | 2008-12-18 | Amgen Inc. | Compositions and methods for producing bioactive fusion proteins |
WO2008153967A1 (en) * | 2007-06-08 | 2008-12-18 | Contec Therapeutics, Inc. | Bk1 antagonist conjugates |
US20100048913A1 (en) | 2008-03-14 | 2010-02-25 | Angela Brodie | Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity |
GB2470700B (en) | 2008-03-25 | 2012-08-08 | Univ Maryland | C-17 heteroaryl steroidal CYP17 inhibitors |
EP3011953A1 (en) | 2008-10-29 | 2016-04-27 | Ablynx N.V. | Stabilised formulations of single domain antigen binding molecules |
WO2010056550A1 (en) | 2008-10-29 | 2010-05-20 | Wyeth Llc | Methods for purification of single domain antigen binding molecules |
US20110312916A1 (en) | 2009-02-05 | 2011-12-22 | Tokai Pharmaceuticals, Inc. | Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens |
US20120121591A1 (en) | 2009-03-20 | 2012-05-17 | Amgen Inc. | SELECTIVE AND POTENT PEPTIDE INHIBITORS OF Kv1.3 |
WO2010110887A1 (en) * | 2009-03-24 | 2010-09-30 | Robert Shorr | Fatty acids |
AU2011277983C1 (en) * | 2010-07-16 | 2016-09-29 | Ablynx Nv | Modified single domain antigen binding molecules and uses thereof |
US8993727B2 (en) | 2010-09-22 | 2015-03-31 | Amgen Inc. | Carrier immunoglobulins and uses thereof |
DE102011118029A1 (de) * | 2011-06-20 | 2012-12-20 | Universität Leipzig | Modifizierte antibiotische Peptide mit variabler systemischer Freisetzung |
US9884067B2 (en) | 2013-03-14 | 2018-02-06 | University Of Maryland, Baltimore | Androgen receptor down-regulating agents and uses thereof |
WO2015023710A1 (en) | 2013-08-12 | 2015-02-19 | Tokai Pharmaceuticals, Inc. | Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies |
US11401303B2 (en) * | 2020-06-15 | 2022-08-02 | Taian City Qihang Biotechnology Co. | Synthetic peptide BRAP and application in preparation of anti-inflammatory drug for COVID-19 thereof |
CA3151034A1 (en) * | 2021-03-03 | 2022-09-03 | Kashiv Biosciences, Llc | Bioassay method for compounds useful to treat pain |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2435642A1 (de) | 1974-07-24 | 1976-02-05 | Hoffmann La Roche | Traegermaterial |
US4693993A (en) | 1985-06-13 | 1987-09-15 | Stewart John M | Bradykinin antagonist peptides |
US4801613A (en) | 1985-06-13 | 1989-01-31 | Nova Technology Limited Partnership | Bradykinin antagonist peptides |
US4923963A (en) | 1987-09-02 | 1990-05-08 | Nova Technology Limited Partnership | Bradykinin antagonist peptides |
EP0318162A3 (en) | 1987-11-25 | 1990-11-07 | Texaco Development Corporation | Novel bismaleimide derivatives |
US5648333A (en) | 1988-11-24 | 1997-07-15 | Hoechst Aktiengesellschaft | Peptides having bradykinin antagonist action |
US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
US5416191A (en) | 1991-04-01 | 1995-05-16 | Cortech, Inc. | Bradykinin antagonists |
US5863899A (en) | 1991-04-01 | 1999-01-26 | Cortech, Inc. | Bradykinin antagonists |
EP0618810B1 (en) | 1991-04-19 | 2001-07-04 | Scios Nova Inc. | Bradykinin antagonist peptides |
US6407207B1 (en) | 1992-03-30 | 2002-06-18 | Merck & Co., Inc. | Cloned and expressed human bradykinin BK-2 receptor |
US5541286A (en) | 1992-10-08 | 1996-07-30 | Scios Nova Inc. | Bradykinin antagonist pseudopeptide derivatives of olefinic aminoalkanoic acids |
US5521158A (en) | 1992-10-08 | 1996-05-28 | Scios Nova Inc. | Pseudopeptide bradykinin receptor antagonists |
US5955430A (en) * | 1993-09-24 | 1999-09-21 | University Of Southern California | Use of angiotensin II fragments and analogs thereof in tissue repair |
CA2184824A1 (en) | 1994-03-09 | 1995-09-14 | Val S. Goodfellow | Bradykinin antagonist peptides incorporating n-substituted glycines |
US5648336A (en) | 1994-11-18 | 1997-07-15 | University Of Colorado | Bradykinin antagonist peptides containing indane-substituted amino acids |
US5849863A (en) | 1995-09-08 | 1998-12-15 | University Of Colorado | Cytolytic bradykinin antagonists |
US5834431A (en) * | 1995-09-08 | 1998-11-10 | Cortech, Inc. | Des-Arg9 -BK antagonists |
WO1998007746A1 (en) | 1996-08-19 | 1998-02-26 | Universite De Sherbrooke | B1-bradykinin receptor antagonists and use thereof |
JP3274076B2 (ja) | 1996-12-16 | 2002-04-15 | セイコーインスツルメンツ株式会社 | ペプチド断片を得る方法 |
US5935932A (en) | 1997-06-13 | 1999-08-10 | University Technology Corporation | Bradykinin antagonists containing pentafluorophenylalanine |
US6388054B1 (en) | 1998-08-20 | 2002-05-14 | John M. Stewart | Anti-cancer compounds |
US6875741B2 (en) * | 1998-09-02 | 2005-04-05 | Renuka Pillutla | Insulin and IGF-1 receptor agonists and antagonists |
WO2001062827A2 (en) | 2000-02-22 | 2001-08-30 | Shearwater Corporation | N-maleimidyl polymer derivatives |
EP2292655B1 (en) * | 2001-05-11 | 2012-03-14 | Amgen SF, LLC | Peptides and related molecules that bind to tall-1 |
US7138370B2 (en) * | 2001-10-11 | 2006-11-21 | Amgen Inc. | Specific binding agents of human angiopoietin-2 |
WO2004032862A2 (en) * | 2002-10-09 | 2004-04-22 | Insert Therapeutics, Inc. | Cyclodextrin-based materials, compositions and uses related thereto |
EP1603392A2 (en) * | 2003-03-07 | 2005-12-14 | The University Of Toledo | Paclitaxel hybrid derivatives |
-
2004
- 2004-10-21 US US10/972,236 patent/US7605120B2/en not_active Expired - Fee Related
- 2004-10-22 BR BRPI0415755-9A patent/BRPI0415755A/pt not_active IP Right Cessation
- 2004-10-22 AU AU2004285467A patent/AU2004285467A1/en not_active Abandoned
- 2004-10-22 JP JP2006536809A patent/JP4896728B2/ja active Active
- 2004-10-22 CA CA002545499A patent/CA2545499A1/en not_active Abandoned
- 2004-10-22 SG SG200900445-8A patent/SG149872A1/en unknown
- 2004-10-22 EP EP04796039A patent/EP1677830B1/en active Active
- 2004-10-22 ES ES04796039T patent/ES2395546T3/es active Active
- 2004-10-22 KR KR1020067009876A patent/KR20060105757A/ko active Search and Examination
- 2004-10-22 EA EA200600817A patent/EA009294B1/ru not_active IP Right Cessation
- 2004-10-22 WO PCT/US2004/034976 patent/WO2005042027A2/en active Application Filing
- 2004-10-22 KR KR1020087002104A patent/KR100860654B1/ko not_active IP Right Cessation
-
2006
- 2006-04-20 IL IL175084A patent/IL175084A0/en unknown
- 2006-05-12 MA MA29025A patent/MA28160A1/fr unknown
- 2006-05-15 NO NO20062198A patent/NO20062198L/no not_active Application Discontinuation
- 2006-05-18 EC EC2006006575A patent/ECSP066575A/es unknown
-
2008
- 2008-04-08 US US12/082,219 patent/US8278280B2/en not_active Expired - Fee Related
- 2008-04-08 US US12/082,224 patent/US8288351B2/en not_active Expired - Fee Related
- 2008-04-09 US US12/082,395 patent/US20090048149A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
KR20060105757A (ko) | 2006-10-11 |
US20090137452A1 (en) | 2009-05-28 |
WO2005042027A2 (en) | 2005-05-12 |
MA28160A1 (fr) | 2006-09-01 |
US8288351B2 (en) | 2012-10-16 |
AU2004285467A2 (en) | 2005-05-12 |
EP1677830A2 (en) | 2006-07-12 |
JP4896728B2 (ja) | 2012-03-14 |
US7605120B2 (en) | 2009-10-20 |
KR20080015054A (ko) | 2008-02-15 |
WO2005042027A3 (en) | 2006-02-09 |
US20090137483A1 (en) | 2009-05-28 |
IL175084A0 (en) | 2006-08-20 |
CA2545499A1 (en) | 2005-05-12 |
BRPI0415755A (pt) | 2006-12-19 |
JP2007526240A (ja) | 2007-09-13 |
US20050215470A1 (en) | 2005-09-29 |
AU2004285467A1 (en) | 2005-05-12 |
ES2395546T3 (es) | 2013-02-13 |
EP1677830B1 (en) | 2012-10-17 |
KR100860654B1 (ko) | 2008-09-26 |
EA200600817A1 (ru) | 2006-12-29 |
SG149872A1 (en) | 2009-02-27 |
US20090048149A1 (en) | 2009-02-19 |
ECSP066575A (es) | 2006-10-17 |
US8278280B2 (en) | 2012-10-02 |
EA009294B1 (ru) | 2007-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20062198L (no) | Bradykinin B1 reseptorantagonister | |
NO340679B1 (no) | Pyridazinonderivativer, farmasøytiske preparater omfattende slike og slike forbindelser og preparater for anvendelse i terapeutisk aktive substanser til behandling og forebygging av sykdommer | |
NO20050807L (no) | Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser | |
NO20044054L (no) | Administrering av midler for behandling av betennelse | |
CL2003002353A1 (es) | Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic | |
TW200605870A (en) | Topical methadone compositions and methods for using the same | |
CY1108932T1 (el) | Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων | |
ATE423114T1 (de) | Aminocyclopropancarbonsäureamidderivate als bradykininantagonisten | |
WO2007062093A3 (en) | Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor | |
WO2006096173A8 (en) | Pharmaceutical compositions and methods for peptide treatment | |
WO2005123192A3 (en) | Improving pain treatment with strontium combinations | |
DE602005002653D1 (de) | Stabilisierte zusammensetzungen mit einem therapeutischen wirkstoff; zitronensäure oder einer konjugierten base und chlordioxid | |
DK1781277T3 (da) | Kombinationssammensætning, der omfatter Ibuprofen og Paracetamol | |
NO20053111L (no) | Peptider som inhiberer angiogenese, cellemigrering, celleinvasjon og celleproliferering. | |
AU2003243719A1 (en) | Topical administration of pharmacologically active bases in the treatment of warts | |
ATE477805T1 (de) | 9a-carbamoyl-y-aminopropyl- und 9a-thiocarbamoyl- y-aminopropyl-azalide mit antimalaria-aktivität | |
WO2008079270A3 (en) | Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis | |
DK1401422T3 (da) | Halogenholdig sammensætning, fremgangsmåde til fremstilling heraf og anvendelser heraf | |
DE602005027231D1 (de) | Cylglycerolen und therapeutischen verwendungen derselben | |
WO2002076439A3 (en) | Compounds capable of modulating the activity of multidrug transporters and therapeutic use of the same | |
EP2510941A3 (en) | Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist | |
ITMI20022292A1 (it) | 9a-azalidi ad attivita' antiinfiammatoria. | |
AU2003229284A1 (en) | Active substances for the treatment, diagnosis and prophylaxis of diseases in which abnormal protein structures occur | |
PT1150704E (pt) | Melagatran para o tratamento da inflamacao | |
WO2006117404A3 (de) | Topische verwendung von radikalfangenden substanzen zur antipyretischen behandlung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |